Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
By: Aly Diana As a disclaimer, I would like to clarify that while I am not an expert in statistics, I am keen on learning and expanding my knowledge. Recently, a professor asked me about the adjustment of multiple comparisons, and my initial reaction was, “Oh noooooo, I totally forgot!” Therefore, I decided to share
By: Yan Mardian An 11-year-old girl has died of bird flu in Cambodia, south-east Asia, and multiple others who live in her area have been sickened, including her father, according to media reports, marking the first known H5N1 human infections in the country since 2014—and potentially setting the stage for sustained human-to-human transmission. The cases
By: Adhella Menur and Retna Mustika Indah On February 5-10, 2023, Adhella Menur, a member of the INA-RESPOND Scientific Team, participated in a two-and-a-half-day grantsmanship workshop and the 12th RePORT India annual meeting in India. The workshop was hosted by CRDF Global in collaboration with the Division of AIDS, NIAID, NIH, to train young investigators
Disclaimer: I am not an AI fanatic. I am just having fun while the free version of ChatGPT is still accessible; so I can make an “evidence-based decision” once the free access is no longer available. The following article was written by the “AI”; without any revisions. I will provide a brief explanation of the
To collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
